Arch Ventures-incubated clinical trials startup leaves stealth with $203M

Chicago, January 27, 2023 (Yahoo) -- The Food and Drug Administration increasingly requires that drug trials are tested on population samples reflective of the people who will use the drug, according to Rebecca Springer, a PitchBook senior healthcare analyst. Paradigm, a clinical trial technology startup, launched out of stealth with a $203 million Series A Friday with hopes to bring research trials to all US patients. The funding slots in as the eighth-largest early-stage healthtech VC deal ever, PitchBook data shows.

Read full article here.